Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Serous Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 26pembrolizumab 17Specimen Handling 17Radiotherapy 17Nivolumab 15Cyclophosphamide 14Temozolomide 11Biopsy 11Fluorodeoxyglucose F18 10fludarabine 9X-Rays 9Etoposide 7Bevacizumab 7Standard of Care 6Radiation 6Paclitaxel 6Dexamethasone 6Cisplatin 6Carboplatin 6Surgical Procedures, Operative 5Ipilimumab 5Doxorubicin 5Aspirin 5venetoclax 4olaparib 4fluciclovine F-18 4atezolizumab 4abemaciclib 4Vincristine 4Rituximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × 3-aminopyridine-2-carboxaldehyde thiosemicarbazone × 1 year × Clear all
NCT04494113 2026-05-13

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Active not recruiting
12 enrolled
Gynecologic

Endometrial Serous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡